Table 2 Six candidate pharmacogenomic variants of most differentiated between three ethnic groups

From: Establishing multiple omics baselines for three Southeast Asian populations in the Singapore Integrative Omics Study

SNP

CHR

POS

Alleles

Gene region

Frequency (Chinese)

Frequency (Malay)

Frequency (Indian)

Clinical PGx implicationa

Wright FST

P empirical

rs2359612

16

31011297

A/G

VKORC1, intron

0.118(G)

0.263(G)

0.900 (G)

(i) Patients with AA genotype who are treated with warfarin may require lowest dose as compared to patients with the AG or GG genotype (ii) Patients with the AG genotype who are treated with warfarin may require lower dose as compared to patients with the GG genotype (iii) Patients with the GG genotype who are treated with warfarin may require higher dose as compared to patients with the AG or AA genotype

0.471

1.23E-05

rs749671

16

30995848

A/G

VKORC1 ZNF646, coding SYN

0.118(G)

0.273(G)

0.900 (G)

NA

0.466

1.31E-05

rs8050894

16

31012010

C/G

VKORC1, intron

0.118(C)

0.263 (C)

0.868 (C)

(i) Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype (ii) Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype (iii) Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to the patients with the CG or CC genotype

0.434

2.33E-05

rs7294

16

31009822

C/T

VKORC1, flanking UTR

0.109(T)

0.272 (T)

0.822(T)

(i) Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or TT genotype (ii) Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype (iii) Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype

0.387

4.79E-05

rs1238741

4

100202335

C/T

ADH4/5, flanking UTR

0.179 (T)

0.272 (T)

0.865 (T)

NA

0.375

5.78E-05

rs11974407

7

20695644

C/G

ABCB5, intron

0.038 (C)

0.165 (C)

0.670(C)

NA

0.361

7.08E-05

  1. aInformation were retrieved from PharmGKB®, only clinical implication with level 2a, 2b, or 1 were retrieved
Back to article page